

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7676590

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CONFIRMATORY ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
THE INSTITUTE FOR CANCER RESEARCH	09/24/2021
RECEIVING PARTY DATA	
Name:	THE INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER
Street Address:	333 COTTMAN AVE
City:	PHILADELPHIA
State/Country:	PENNSYLVANIA
Postal Code:	19111
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	9346814
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	kcarlson@stradley.com
Correspondent Name:	KEVIN CASEY
Address Line 1:	30 VALLEY STREAM PARKWAY
Address Line 2:	STRADLEY RONON
Address Line 4:	MALVERN, PENNSYLVANIA 19355
ATTORNEY DOCKET NUMBER:	185300-0024
NAME OF SUBMITTER:	KEVIN R CASEY
SIGNATURE:	/Kevin R. Casey/
DATE SIGNED:	12/05/2022
Total Attachments: 3	
source=Confirmatory_Assignment_of_Patent_Rights#page1.tif	
source=Confirmatory_Assignment_of_Patent_Rights#page2.tif	
source=Confirmatory_Assignment_of_Patent_Rights#page3.tif	

CONFIRMATORY ASSIGNMENT OF PATENT RIGHTS

WHEREAS, The Fox Chase Cancer Center (“FCCC”) a Pennsylvania nonprofit corporation located at 333 Cottman Ave, Philadelphia PA 19111, USA, is a National Cancer Institute-designated Comprehensive Cancer Center research facility and hospital;

WHEREAS, on March 15, 2012, The Institute for Cancer Research (“The Institute”), a Delaware nonprofit corporation located at 333 Cottman Ave, Philadelphia PA 19111, USA, filed an Application for Registration of Fictitious Name with the Pennsylvania Department of State authorizing it to do business as “The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center”;

WHEREAS, on June 28, 2012, FCCC filed Articles of Amendment-Domestic Corporation with the Pennsylvania Department of State changing its name to “The Fox Chase Cancer Center Foundation” (“The Foundation”), which was recorded by the Pennsylvania Department of State beginning at Microfilm Reel 193 Frame 567;

WHEREAS, Jonathan D. Cheng (“Inventor”), an employee of FCCC, created an invention entitled “NOVEL FAP INHIBITORS” for which a GB Patent Application was filed on November 14, 2012, with Application number 1220458.2 (“Invention”);

WHEREAS, in accordance with his contract of employment, by assignment dated December 12, 2012, and recorded with the United States Patent and Trademark Office on October 13, 2014 beginning at Reel 033935 Frame 0599 (“Inventor’s Assignment”), Inventor conveyed to FCCC and its assigns, successors, and legal representatives, the entire and exclusive right, title, and interest in and to the aforesaid Invention, including the right to sue for and recover for past damages along with any tangible materials embodied in or encompassed by the Invention and in and to an application for a European Patent (which became EP 2 804 859), its member states and possessions and all foreign countries, including rights to claim priority, to any provisional applications, and in and to any Letters Patent of the United States (which became U.S. Patent No. 9,346,814) or any foreign country which may be granted therefore, including any and all reissues, divisions, continuations, continuations-in-part, renewals, substitutes or extensions thereof (the “Rights”), for the use and benefit of FCCC and its assigns, its successors and legal representatives, in as ample and beneficial manner to all intents and purposes as FCCC might or could have held and enjoyed the same, if the assignment had not been made;

WHEREAS, as part of the Inventor’s Assignment, Inventor agreed to execute all papers that may be necessary to file patent applications for the Invention and to assign the same to FCCC or its assigns, its successors or legal representative and to execute any other papers that may be needed in connection with filing the patent applications and securing the aforesaid Rights and Inventor authorized and request the Commissioner of Patents and Trademarks to issue Letters Patent on the patent applications, and on any and all divisions and continuations thereof, to FCCC, its assigns, its successors and legal representatives, in accordance therewith;

WHEREAS, pursuant to an Assignment and Affiliation Agreement effective July 1, 2012 (“Agreement”), by assignment effective July 1, 2012, and recorded with the United States Patent and Trademark Office on June 8, 2020, beginning at Reel 053562 Frame 0938, The Foundation conveyed its Rights in EP 2 804 859 and U.S. Patent No. 9,346,814 to The Institute, including the right to sue for and recover for past damages;

WHEREAS, Inventor and The Foundation (collectively the “Assignors”) wish to confirm

the transfer of the Rights in the Invention, including EP 2 804 859 and U.S. Patent No. 9,346,814, to The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center ("Assignee");

NOW THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors confirm they have assigned, and by these presents, to the extent necessary, do assign to Assignee all right, title and interest in and to the Invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on the same in the United States (including U.S. Patent No. 9,346,814) and all countries throughout the world (including EP 2 804 859), and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Confirmatory Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.


Assignors further agree that they will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the Invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the Invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN TESTIMONY WHEREOF, Assignors have signed on the date(s) opposite the undersigned name(s).


INVENTOR

Date: September 29, 2021


Name: Jonathan D. Cheng, MD
Title: Adjunct Associate Professor

THE INSTITUTE FOR CANCER
RESEARCH d/b/a THE RESEARCH
INSTITUTE OF THE FOX CHASE
CANCER CENTER

Date: 9/24/2021


Name: Kurt A. Schwinghammer, Ph.D.
Title: Vice President, R&D Alliances

THE FOX CHASE CANCER CENTER
FOUNDATION

Date: 9/24/21


Name: Ray Lynch
Title: Chief Financial Officer